The research was in part supported by the National Institute for Health Research infrastructure at Leeds.Ĭompeting interests AMM holds a fellowship from the British Heart Foundation in support of this study (FS/3). Boehringer-Ingelheim UK Ltd provided the study drugs (alteplase 10 mg, 20 mg and matched placebo). T-TIME was supported by grant 12/170/4 from the Efficacy and Mechanism Evaluation (EME) programme of the National Institute for Health Research (NIHR-EME). CB is supported by grants from the British Heart Foundation (RE/7 FS/3). CB is guarantor.įunding AMM is funded by a fellowship from the British Heart Foundation (FS/3). KAAF, RCT and NC contributed to interpreting the data and revising the work critically for intellectual content. JG, KGO, MM, CB, DM, SC, AHG, CA, HE, JC, AW and NC contributed to data acquisition. PMcC and CB analysed the magnetic resonance images. AMM, PD and AM performed the statistical analyses. AMM, CB and MM performed the angiogram analyses. AMM and CB conceived the idea for the manuscript. Professor Colin Berry, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK .uk 15 Department of Cardiology, University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, UK.14 Electrocardiology Group, Royal Infirmary, Glasgow, UK.13 Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK.12 Wessex Cardiac Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.11 Barts and The London Hospital, London, UK.10 Department of Cardiology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, Wolverhampton, UK.9 Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK.8 Division of Cardiology, University of Leicester, Leicester, UK.7 Manchester University NHS Foundation Trust, Manchester, UK.6 James Cook University Hospital, Middlesbrough, UK.5 Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.4 Department of Cardiology, Leeds General Infirmary, Leeds, UK.3 Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.2 British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.1 Department of Cardiology, Golden Jubilee National Hospital, Glasgow, UK.T-TIME (Trial of low-dose adjunctive alTeplase during primary PCI) investigators.The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. TIMI risk score accurately risk stratifies patients with undifferentiated chest pain presenting to an emergency department. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Morrow DA, Antman EM, Charlesworth A et-al. female first-degree relative or mother younger than 65 yearsĪ percentage risk at 14 days of all-cause mortality, new or recurrent myocardial infarction, or severe recurrent ischemia requiring urgent revascularization.male first-degree relative or father younger than 55 years.family history of premature coronary artery disease.hypertension >140/90 mmHg or on anti-hypertensives.at least 3 risk factors for coronary artery disease, which include:.known coronary artery disease (CAD) (coronary stenosis ≥50%). ST changes of at least 0.5 mm in contiguous leads.at least 2 angina episodes in the last 24 hours.aspirin use within the last 7 days (patient has chest pain despite as required use in past 7 days).It is thought to have potential to improve the management of patients presenting to hospital with undifferentiated chest pain where ischemic heart disease is a potential diagnosis 3. The thrombolysis in myocardial infarction (TIMI) risk score is a prognostic risk stratification system that categorizes the risk of death and ischemic events in patients with unstable angina / non-ST elevation myocardial infarction and provides a basis for therapeutic decision making.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |